#United States #Philadelphia #Securities Fraud #Berger Montague #MoonLake Immunotherapeutics

Class Action Notice for MoonLake Investors

On November 11, 2025, Berger Montague, a prominent national plaintiffs' law firm, announced a class action lawsuit against MoonLake Immunotherapeutics (NASDAQ: MLTX). This lawsuit is particularly significant for investors who purchased shares of MoonLake during the specified class period from March 10, 2024, to September 29, 2025. Investors are urged to act by December 15, 2025, to seek appointment as lead plaintiff representatives of the class.

Background of the Case

MoonLake Immunotherapeutics, headquartered in Zug, Switzerland, is a biopharmaceutical company known for developing therapies aimed primarily at treating inflammatory diseases. The core of this lawsuit revolves around claims that the company engaged in misleading practices by aggressively promoting its primary drug candidate, sonelokimab (SLK), as having significant clinical superiority compared to competing therapies. This assertion is based on its unique Nanobody structure.

However, the lawsuit alleges that MoonLake did not adequately disclose vital information: specifically, that SLK targets the same biological molecules as the FDA-approved drug BIMZELX. Moreover, the complaint argues that there was no evident clinical advantage of SLK over existing treatments.

Critical Disclosure and Stock Impact

On September 28, 2025, MoonLake released data from its Phase 3 clinical trials which revealed that SLK did not achieve efficacy levels comparable to BIMZELX. This bombshell announcement significantly impacted investor confidence, leading to analysts describing the trial outcomes as “disastrous.” The fallout was immediate, with the company's stock plummeting by $55.75, representing a staggering 90% decline in just one day of trading.

Investor Options

Investors who believed in MoonLake’s potential face the frustration of significant losses due to alleged misrepresentation and lack of transparency from the company. In light of this class action suit, affected investors are encouraged to explore their options regarding holding MoonLake accountable for their investments.

Berger Montague is committed to helping investors navigate this challenging situation. Those interested in pursuing their rights are invited to reach out for in-depth consultations. Additional inquiries can be directed to:

• - Andrew Abramowitz at [email protected] or (215) 875-3015
• - Caitlin Adorni at [email protected] or (267) 764-4865

About Berger Montague

Founded in 1970, Berger Montague has become a leading force in securities class action litigation. With offices across major U.S. cities, including Philadelphia, Washington, D.C., and San Francisco, the firm has a steadfast commitment to representing both individual and institutional investors. They offer expertise in navigating complex legal landscapes, especially in securities fraud cases.

For further information or to discuss this class action, investors can contact Andrew Abramowitz, Senior Counsel at Berger Montague, at (215) 875-3015.

Conclusion

The upcoming deadline of December 15, 2025, is crucial for investors affected by the performance and declarations of MoonLake Immunotherapeutics. The developments surrounding this class action suit serve as a reminder of the ongoing need for vigilance and diligence in the investment landscape. Investors are strongly urged to take action promptly to protect their rights within the framework of this case.